GlassScriptPhysician profile
Mia Norlin
NPI 1124079744
$2,479.20
in general payments reported to CMS, 2019-2025
23 companies · $497 in 2025
The $497 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $187 · 2021: $415 · 2022: $269 · 2023: $540 · 2024: $353 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.22 | 2019-2025 | |
| Hologic Sales and Service, LLC | $284.20 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Coopersurgical, INC. | $190.49 | 2019-2025 | Endosee, Paragard T 380a |
| Allergan, INC. | $150.74 | 2019-2020 | |
| Millicent US INC | $90.95 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Biogen, INC. | $76.45 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $73.17 | 2021-2023 | Balcoltra |
| Organon LLC | $68.23 | 2023-2025 | Nexplanon, Nuvaring |
| Exeltis, USA INC. | $66.88 | 2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $60.46 | 2023-2025 | |
| Astellas Pharma US INC | $52.58 | 2024 | Veozah |
| Exact Sciences Corporation | $40.37 | 2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $38.73 | 2020-2021 | |
| Channel Medsystems, INC. | $38.73 | 2025 | |
| Aspira Women'S Health INC | $35.99 | 2020-2024 | Ova1 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $33.29 | 2023 | Accrufer |
| Pfizer INC. | $23.01 | 2024 | |
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.30 | 2025 | |
| Mayne Pharma Commercial LLC | $18.24 | 2024 | |
| Evofem Biosciences, INC. | $17.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Norlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.